Prospera Energy Inc. Announces Increased Working Interest in Core Properties
September 05, 2024 04:00 ET
|
Prospera Energy Inc.
CALGARY, Alberta, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. (PEI: TSX-V; OF6A: FRA) ("Prospera" or the "Corporation") Prospera Energy is pleased to announce a 17% working interest...
Draganfly Confirms Post-Consolidation Trading Date
August 30, 2024 07:15 ET
|
Draganfly Inc
Vancouver, BC., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems...
Entscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea aus
August 27, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 27. August 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,...
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
August 27, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company...
Draganfly Announces Effective Date of Share Consolidation
August 23, 2024 16:30 ET
|
Draganfly Inc
Vancouver, BC., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems...
Draganfly Announces Closing of US$2.0 Million Registered Direct Offering
August 21, 2024 18:29 ET
|
Draganfly Inc
Saskatoon, SK., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), a drone solutions, and systems developer, today announced that...
Starke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
August 21, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, 21. August 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren...
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
August 21, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, Switzerland, August 21, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
Draganfly Announces Pricing of US$2.0 Million Registered Direct Offering
August 20, 2024 08:00 ET
|
Draganfly Inc
Saskatoon, SK., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), a drone solutions, and systems developer, today announced that...
Draganfly Announces 30% Quarter Over Quarter Revenue Increase with Second Quarter Results for 2024
August 13, 2024 16:50 ET
|
Draganfly Inc
Vancouver, BC., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems...